BACKGROUND: The immunogenicity of pneumococcal conjugate vaccine (PCV) has not been evaluated in HIV-infected infants following the first and second PCV-doses. We studied antibody kinetics of serotypes included in 7-valent PCV in HIV-infected and HIV-uninfected infants prior to and following each of three PCV-doses. METHODS:HIV-uninfected infants born to HIV-uninfected (HUU) and HIV-infected mothers (HEU); and perinatal HIV-infected children with CD(4+)<25% randomized to initiate antiretroviral treatment (ART) when clinically and/or immunologically indicated (ART-) or immediately (ART+) were enrolled. Vaccination occurred at approximately 7.4, 11.5 and 15.5 weeks of age. Serotype-specific antibody was measured by ELISA following each PCV-dose and opsonophagocytic activity (OPA) to three serotypes following the second and third doses. RESULTS:Pre-vaccination, antibody geometric mean concentrations (GMCs) were higher in HUU compared to HIV-exposed groups for most serotypes. GMCs and proportion of infants with antibody ≥0.35 μg/ml were similar in HUU compared to other groups following the second PCV-dose. In all groups, GMCs were greater following the third compared to post-second dose; and a higher proportion within each group had antibody ≥0.35 μg/ml to 6B and 23F. OPA GMTs increased after the third compared to post-second dose for studied-serotypes; as did the proportion with OPA ≥8 to 23F. CONCLUSION: A two-dose primary-series of PCV probably confers similar protection against invasive pneumococcal disease in HIV-infected compared to HUU children. The inferior response to serotypes 6B and 23F, and lower GMCs and OPA GMTs, following two compared to after three PCV-doses may have implications in the prevention of pneumococcal disease in high-burden countries.
RCT Entities:
BACKGROUND: The immunogenicity of pneumococcal conjugate vaccine (PCV) has not been evaluated in HIV-infectedinfants following the first and second PCV-doses. We studied antibody kinetics of serotypes included in 7-valent PCV in HIV-infected and HIV-uninfectedinfants prior to and following each of three PCV-doses. METHODS:HIV-uninfected infants born to HIV-uninfected (HUU) and HIV-infected mothers (HEU); and perinatal HIV-infectedchildren with CD(4+)<25% randomized to initiate antiretroviral treatment (ART) when clinically and/or immunologically indicated (ART-) or immediately (ART+) were enrolled. Vaccination occurred at approximately 7.4, 11.5 and 15.5 weeks of age. Serotype-specific antibody was measured by ELISA following each PCV-dose and opsonophagocytic activity (OPA) to three serotypes following the second and third doses. RESULTS: Pre-vaccination, antibody geometric mean concentrations (GMCs) were higher in HUU compared to HIV-exposed groups for most serotypes. GMCs and proportion of infants with antibody ≥0.35 μg/ml were similar in HUU compared to other groups following the second PCV-dose. In all groups, GMCs were greater following the third compared to post-second dose; and a higher proportion within each group had antibody ≥0.35 μg/ml to 6B and 23F. OPA GMTs increased after the third compared to post-second dose for studied-serotypes; as did the proportion with OPA ≥8 to 23F. CONCLUSION: A two-dose primary-series of PCV probably confers similar protection against invasive pneumococcal disease in HIV-infected compared to HUU children. The inferior response to serotypes 6B and 23F, and lower GMCs and OPA GMTs, following two compared to after three PCV-doses may have implications in the prevention of pneumococcal disease in high-burden countries.
Authors: Katherine A Poehling; Thomas R Talbot; Marie R Griffin; Allen S Craig; Cynthia G Whitney; Elizabeth Zell; Catherine A Lexau; Ann R Thomas; Lee H Harrison; Arthur L Reingold; James L Hadler; Monica M Farley; Bridget J Anderson; William Schaffner Journal: JAMA Date: 2006-04-12 Impact factor: 56.272
Authors: Shabir A Madhi; Locadiah Kuwanda; Clare Cutland; Anne Holm; Helena Käyhty; Keith P Klugman Journal: Pediatr Infect Dis J Date: 2005-05 Impact factor: 2.129
Authors: Elske J M van Gils; Reinier H Veenhoven; Eelko Hak; Gerwin D Rodenburg; Debby Bogaert; Ed P F Ijzerman; Jacob P Bruin; Loek van Alphen; Elisabeth A M Sanders Journal: JAMA Date: 2009-07-08 Impact factor: 56.272
Authors: Katherine L O'Brien; Lara J Wolfson; James P Watt; Emily Henkle; Maria Deloria-Knoll; Natalie McCall; Ellen Lee; Kim Mulholland; Orin S Levine; Thomas Cherian Journal: Lancet Date: 2009-09-12 Impact factor: 79.321
Authors: Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre Journal: N Engl J Med Date: 2008-11-20 Impact factor: 91.245
Authors: Wendy Mphatswe; Natasha Blanckenberg; Gareth Tudor-Williams; Andrew Prendergast; Christina Thobakgale; Nompumelelo Mkhwanazi; Noel McCarthy; Bruce D Walker; Photini Kiepiela; Philip Goulder Journal: AIDS Date: 2007-06-19 Impact factor: 4.177
Authors: Shabir A Madhi; Alane Izu; Marta C Nunes; Avye Violari; Mark F Cotton; Patrick Jean-Philippe; Keith P Klugman; Anne von Gottberg; Nadia van Niekerk; Peter V Adrian Journal: Vaccine Date: 2015-04-21 Impact factor: 3.641
Authors: Catherine Satzke; Eileen M Dunne; Barbara D Porter; Keith P Klugman; E Kim Mulholland Journal: PLoS Med Date: 2015-11-17 Impact factor: 11.069
Authors: Cheryl Cohen; Claire von Mollendorf; Linda de Gouveia; Nireshni Naidoo; Susan Meiring; Vanessa Quan; Vusi Nokeri; Melony Fortuin-de Smit; Babatyi Malope-Kgokong; David Moore; Gary Reubenson; Mamokgethi Moshe; Shabir A Madhi; Brian Eley; Ute Hallbauer; Ranmini Kularatne; Laura Conklin; Katherine L O'Brien; Elizabeth R Zell; Keith Klugman; Cynthia G Whitney; Anne von Gottberg Journal: Clin Infect Dis Date: 2014-06-09 Impact factor: 9.079